RPMI 8226 Cells

Categories: Myeloma cell lines Description: RPMI 8226 cells are a human myeloma cell line that was established in 1966 from the peripheral blood of a 61-year-old male patient with multiple myeloma. This cell line was named after the Roswell Park Memorial Institute (RPMI) where it was developed, and the number 8226 denotes its specific catalog number in the cell bank. The RPMI 8226 cell line is an important model system for studying multiple myeloma and related aspects of plasma cell biology, immunology research, and cancer therapy. RPMI 8226 cells are known to produce and secrete kappa light chains of immunoglobulins, a feature that is often exploited in research studies to investigate antibody production and secretion mechanisms. RPMI 8226 cells exhibit numerous chromosomal abnormalities, which are typical of multiple myeloma cells. These include translocations, deletions, and amplifications that affect various oncogenes and tumor suppressor genes. The human myeloma cell line RPMI 8226 are widely used in drug discovery and development research, and have been used to investigate drug resistance pathways and evaluating combination therapies. In summary, RPMI 8226 cells provide a critical in vitro model for multiple myeloma research, enabling the investigation of the biological and molecular mechanisms underlying this disease and the development of therapeutic strategies. Organism: Human Tissue: Peripheral blood Disease: Multiple Myeloma Synonyms: RPMI-8226, RPMI.8226, RPMI8226, RPMI no. 8226, RPMI no 8226, RPMI #8226, 8226, RPMI 8226/S, RPMI-8226S, RPMI8226/S, 8226/S, Roswell Park Memorial Institute 8226, GM02132, GM2132, GM 2132, GM02132C, Simpson Age: 61 years Gender: Male Morphology: Round cells Growth Properties: Adherent/suspension Citation: RPMI 8226 (Cytion catalog number 300431) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_0014 Antigen Expression: HLA Aw19, B15, B37, Cw2 Isoenzymes: G6PD, A Reverse Transcriptase: Negative Products: Immunoglobulin light chain Culture Medium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) Supplements: Supplement the medium with 10% FBS Dissociation Reagent: Accutase Subculturing: Gather the suspension cells in a 15 ml tube and gently wash the adherent cells with PBS lacking calcium and magnesium (use 3-5 ml for T25 flasks and 5-10 ml for T75 flasks). Apply Accutase (1-2 ml for T25 flasks, 2.5 ml for T75 flasks) ensuring full coverage of the cell layer. Allow the cells to incubate at room temperature for 10 minutes. Following incubation, combine and centrifuge both the suspension and adherent cells. After centrifugation, carefully resuspend the cell pellet and transfer the cell suspension into new flasks containing fresh medium. Seeding Density: Start new cultures at 5 x 105 viable cells/ml. Subculture at 1-2 x 106 cells/ml. Maximum cell density is at 1-2 x 106 cell/ml. Fluid Renewal: 2 to 3 times per week Post Thaw Recovery: After thawing allow the cells to recover from the freezing process for at least 24 hours. Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 1: 820700a Required Product 3: 860015.0 Required Product 4: 830100.0